cardiovascular system
• terminal erythrocyte velocity is increased (17.1+/-5.2 compared to 3.3+/-3.3 mm per second in wild-type mice)
|
• ATPase and ADPase activities are substantially decreased compared to in wild-type mice
|
hematopoietic system
• platelet count is 20% lower than in wild-type mice (538+/-78x103 per mm3 compared to 740+/-81x103 per mm3 in wild-type mice)
|
• polymorphonuclear (PMN) cells fail to convert etheno-AP into etheno-AMP as do wild-type PMNs
• following activation, the supernatant surrounding PMNs accumulate 1.6+/-0.09-fold more ATP than from wild-type PMNs
• unactivated PMN supernatant accumulates more ATP than wild-type
|
• in vitro, platelets fail to aggregate in response to ADP, collagen or low doses of thrombin
• however, treatment with a soluble potato ATPase restores aggregation response
|
homeostasis/metabolism
• in vitro, platelets fail to aggregate in response to ADP, collagen or low doses of thrombin
• however, treatment with a soluble potato ATPase restores aggregation response
|
• bleed time is increased to greater than 20 minutes in 4 mice and greater than 7 minutes in 7 mice compared to 1.0+/-0.2 minutes in heterozygous mice
• treatment with ferric chloride revealed a delay in platelet plug formation with no thrombi formation after 20 minutes compared to 100% in wild-type mice
|
immune system
• polymorphonuclear (PMN) cells fail to convert etheno-AP into etheno-AMP as do wild-type PMNs
• following activation, the supernatant surrounding PMNs accumulate 1.6+/-0.09-fold more ATP than from wild-type PMNs
• unactivated PMN supernatant accumulates more ATP than wild-type
|
respiratory system
• fibrin deposits are present in the lungs and worsen after thrombogenic challenge
|
liver/biliary system
renal/urinary system
nervous system
• mice exhibit increased fibrin deposits in the brain
|